

Seasonal Flu Vaccine (Influenza)

In **Germany**, seasonal flu waves typically occur during the winter months, usually after the turn of the year. Last year as well, the number of cases rose sharply from mid-December, peaking in early February. Many symptoms of influenza are quite similar to a common cold. The main difference is that a common cold is an airway condition, whereas influenza causes systemic symptoms. It often develops quickly and could lead to serious symptoms, which usually improve within a week.

A mild course of influenza infection without fever can be common and facilitates the rapid spread of the disease. The flu virus as well as corona viruses are transmitted among humans via airborne droplets, i.e. through coughing or sneezing on another person. Hand shaking can also lead to a transmission of these viruses.

The characteristic flu symptoms begin two to three days after infection, characterized by **sudden** onset (within hours) with a **rapid systemic deterioration** and **high fever**, as well as a **dry and painful cough** and **severe headache, limb and muscle pain**. In contrast to the common cold, **rhinitis is not a frequent symptom**. Recovery takes days to weeks, fatigue and coughing could persist even longer.

The best protection against the flu is the Influenza vaccination, which should be repeated annually.

Vaccination is especially recommended for people who are at an increased risk of severe disease or who are particularly susceptible to influenza infection. The influenza vaccines recommended for adults in Germany are inactivated vaccines. This means, the vaccination itself cannot cause the disease, nor can vaccine viruses be passed on to third parties. The vaccination is carried out as a single inoculation into the upper arm muscle, the most favourable time being between September and November. The protective effect begins about 1-2 weeks after vaccination and prevents against more than half of all flu infections.

According to the WHO recommendation from September 2023, only trivalent flu vaccines will be available starting in 2025. The reason for this is that the inclusion of the B/Yamagata component is no longer considered necessary, as these viruses have not been detected since March 2020.

Vaccine composition in 2026/2027 of cell culture-based vaccines according to the WHO (northern hemisphere):

- A(H1N1)pdm09: an A/Missouri/11/2025-like virus
- A(H3N2): an A/Darwin/1415/2025-like virus
- B/Victoria lineage: a B/Pennsylvania/14/2025-like virus

The Standing Committee on Immunization at Robert-Koch-Institute (STIKO) recommends the vaccination for:

- **Individuals with an increased health risk** as a result of an underlying disease (e.g. asthma, heart disease, diabetes, liver or kidney disease or MS)
- **All pregnant women**, STIKO recommends vaccination from the second trimester of pregnancy onwards
- **Individuals with an increased occupational risk, such as healthcare personnel**
- **Individuals who may be a source of infection** for persons at risk under their care
- Individuals with increased risk via direct contact to poultry and wild birds
- Travelers according to risk and vaccine availability, in the event of an impending or expected epidemic in accordance with the recommendations of the health authorities.
- **For individuals over 60 years of age, a high-dose vaccine (e.g., Efluelda®) is recommended.** This vaccine contains **four times the amount of antigen per virus strain (without adjuvants)** compared to standard-dose flu vaccines. The higher antigen content is intended to offer better protection against influenza. However, vaccination with the standard dose is also possible: in such cases, the protective effect is likely to be slightly lower. Since Efluelda® is also produced **using chicken egg protein**, individuals with an egg allergy should only receive the vaccine after consulting a physician. The same applies to those with a **formaldehyde allergy**.
- Children and adolescents aged 2-17 years of age for whom influenza vaccination is indicated, vaccination is recommended either with the nasally administered trivalent live influenza vaccine (LAIV) or with the inactivated influenza vaccine (IVV) as long as there is no contraindication.

Possible vaccination reactions and side effects

The flu vaccine is generally well tolerated, even pregnant women have been regularly vaccinated for many years. Occasionally, the stimulation of the immune system after vaccination may cause redness or swelling locally at the injection site, which may be painful. Similarly, systemic symptoms such as chills, fatigue, nausea or muscle aches may occur in the first three days after the vaccination. Such vaccination reactions usually subside after one to three days.

Side effects are very rare. In less than one in 10,000 vaccinated individuals, allergic reactions were observed on the skin and in the airways. Small blood vessels may also become inflamed in rare circumstances, or the number of platelets (responsible for blood clotting) can temporarily decrease.

Important note: Since Flucellvax® is grown in cell cultures, it is the method of choice for persons with a proven severe egg protein allergy. Vaccination is possible here without the special precautions required for egg-based vaccines (such as Influsplit® or Efluelda®).

For further detailed and reliable information on the influenza vaccine, please visit [Sicherheit und Wirksamkeit der Grippeimpfung – englisch](#) or <https://www.informedhealth.org/influenza.html> or [RKI - Information sheets about vaccinations in various languages - Vaccine information sheet: Influenza](#) (RKI fact sheets on vaccination)